Amphion Innovations plc
Additional Terms on Loan Facility
London and New York, 29 April 2016 - On 28 April, Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announced that the Company had agreed terms for the draw-down of an additional tranche of US $1,765,000 (an “Additional Draw”) under the loan facility as announced on 5 June 2014 (the “Facility”).
Additional terms of the Facility allow the conversion of the drawn-down amount into ordinary shares in Amphion (“Ordinary Shares”). Up to US $500,000 of the Facility may be converted at 6.5 pence per Ordinary Share and the remainder of the amount drawn-down under the Facility, approximately US $3.6 million, may be converted at 8.0 pence per Ordinary Share.
For further information please contact
+1 212 210 6224
Yellow Jersey PR
Charles Goodwin / Dominic Barretto
+44 (0)7747 788 221
Panmure Gordon Limited (Nominated Adviser and Corporate Broker)
Freddy Crossley / Duncan Monteith (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500
Northland Capital Partners Limited (Joint Corporate Broker)
Patrick Claridge / David Hignell (Corporate Finance)
John Howes (Corporate Broking)
+44 (0)20 7382 1100
Plumtree Capital Limited (Financial Adviser)
+44 (0)20 7183 2493
+646 568 7502
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.
We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.